MOG (35-55)
(Synonyms: 髓鞘少突胶质细胞糖蛋白,endrocyte Glycoprotein Peptide (35-55)) 目录号 : GC17193
MOG (35-55)是髓磷脂少突胶质细胞糖蛋白的35-55片段。
Cas No.:149635-73-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MOG (35-55) is a 35-55 fragment of myelin oligodendrocyte glycoprotein [1]. Immunizing mice with MOG (35-55) peptide to induce experimental autoimmune encephalomyelitis (EAE), it causes inflammation (macrophages and CD3+ T lymphocytes), demyelination, and axonal loss [1]. MOG (35-55) is often used to model EAE in mice for evaluating various drug treatments [2].
Axon loss in the medial dorsal column (fasciculus gracilis), which is often damaged in this model of EAE, was detected as early as 7 days post-immunization (p.i.), with a loss of about 11% of axons in the defined counting area. A further 10% loss was observed by day 12 p.i., at which time behavioral disease was just beginning to become apparent [1]. T lymphocytes were detected infiltrating the spinal cord as early as day 7 p.i. CD3-immunoreactivity increased 5-fold [1]. MOG (35-55) immunized mice developed severe parenchymal infiltration in the spinal cords on day 9, day 13 and day 16, and mice showed heavy infiltration of the cerebral meninges, which prevailed in the region of the hippocampus involving the lateral and the third ventricle [3]. MOG (35-55)-induced EAE showed the cerebellar white matter infiltrates in all mice on days 13 and 16 [3].
References:
[1]. Jones M V, Nguyen T T, Deboy C A, et al. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis[J]. Journal of neuroimmunology, 2008, 199(1-2): 83-93.
[2]. Steinman L, Zamvil S S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis[J]. Trends in immunology, 2005, 26(11): 565-571.
[3]. Kuerten S, Kostova-Bales D A, Frenzel L P, et al. MP4-and MOG: 35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum[J]. Journal of neuroimmunology, 2007, 189(1-2): 31-40.
| Cell experiment [1]: | |
|
Cell lines |
|
|
Preparation Method |
To prepare T cell lines specific for MOG (35-55) peptide, C57BL/6 mice were immunized s.c. in the flanks with 0.2 ml of an emulsion containing 200 µg of MOG (35-55) in saline and an equal volume of CFA containing 400 µg Mycobacterium tuberculosis H37RA. Ten days after immunization, lymph node cells were cultured with MOG (35-55) (20 µg/ml) at 8 × 106 cells/ml in stimulation medium (RPMI 1640 medium supplemented with nonessential amino acids, sodium pyruvate, 2-ME, and 10% FBS) for 48 h. The T cells were expanded in medium containing IL-2 (100 U/ml). |
|
Reaction Conditions |
20 µg/ml, 5-10 days |
|
Applications |
After 5-10 days in culture, the T cell lines responded specifically to MOG (35-55) peptide. |
| Animal experiment [2]: | |
|
Animal models |
6-8 weeks old female C57BL/6 mice |
|
Preparation Method |
Mice were immunized subcutaneously at the base of the tail with 100 µl of mouse MOG (35-55) peptide emulsified in complete Freund's adjuvant (CFA). Peptide was dissolved in phosphate-buffered saline (PBS) at 2 mg/ml, mixed at a 1:1 ratio with complete adjuvant (8 mg/ml heat-killed Mycobacterium tuberculosis (H37 RA) in incomplete Freund's adjuvant (IFA)), and emulsified by the syringe-extrusion method with two rubber-free Luer-Lock syringes (Air-Tite) connected by a 3-way stopcock until a stable emulsion was formed (approx. 10 min). Each mouse received 100 µg of peptide (and 400 µg of M. tuberculosis). On the day of immunization and two days later, 250 ng of pertussis toxin in 100 µl PBS was administered intravenously. |
|
Dosage form |
Subcutaneous injection, 100 µg in 100 µl |
|
Applications |
Immunization of C57BL/6 mice with MOG (35-55) caused inflammation and axon loss in the spinal cord but resulted in only minimal demyelination |
|
References: [1]: Ito A, Matejuk A, Hopke C, et al. Transfer of severe experimental autoimmune encephalomyelitis by IL-12-and IL-18-potentiated T cells is estrogen sensitive[J]. The Journal of Immunology, 2003, 170(9): 4802-4809. | |
| Cas No. | 149635-73-4 | SDF | |
| 别名 | 髓鞘少突胶质细胞糖蛋白,endrocyte Glycoprotein Peptide (35-55) | ||
| 化学名 | (S)-2-((Z)-((2S,3R)-3-amino-1,2-dihydroxy-4-phenylbutylidene)amino)-4-methylpentanoic acid compound with 2,2,2-trifluoroacetic acid (1:1) | ||
| Canonical SMILES | CC(C[C@@](/N=C(O)/[C@](O)([H])[C@@](N)([H])CC1=CC=CC=C1)([H])C(O)=O)C.FC(F)(F)C(O)=O | ||
| 分子式 | C118H177N35O29S | 分子量 | 2581.97 |
| 溶解度 | ≥ 32.25mg/mL in Water, ≥ 86 mg/mL in DMSO | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3873 mL | 1.9365 mL | 3.873 mL |
| 5 mM | 0.0775 mL | 0.3873 mL | 0.7746 mL |
| 10 mM | 0.0387 mL | 0.1937 mL | 0.3873 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet